Silverlon to Reduce Radiation Dermatitis

Condition:   Radiation Dermatitis Intervention:   Device: Silverlon Sponsors:   University of Rochester;   Biomedical Advanced Research and Development Authority Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusion: Bathing with pine-tar is an efficacious and recommendable adjuvant practice for AD patients. Disease improvement is associated with reduction of SA and IgE. PMID: 32066302 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Authors: Kim HY, Ahn SH, Yang IJ, Park SY, Kim K Abstract The aim of this study was to investigate the efficacy of Hataedock (HTD) on skin barrier maintenance through the endocannabinoid system (ECS) intervention in Dermatophagoides farinae-induced atopic dermatitis (AD) NC/Nga mice. Douchi (fermented Glycine max Merr.) extracts prepared for HTD were orally administered to NC/Nga mice at a 20 mg/kg dose. Then, Dermatophagoides farinae extract (DfE) was applied to induce AD-like skin lesions during the 4th-6th and 8th-10th weeks. Changes in the epidermal structure of the mice were observed by histochemistry, ...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
AbstractPurpose of ReviewIrritant contact dermatitis (ICD) is defined as a localized skin reaction to irritants which does not require prior sensitization of the immune adaptative system. ICD is a consequence of direct toxic effect of physical or chemical agents resulting in keratinocyte damage. The purpose of this review was to highlight the various aspects of ICD to improve its management.Recent FindingsIt is now known that ICD is a complex reaction that involved both endogenous and exogenous factors, and does not represent a homogenous entity but can cover various clinical subtypes. The management of ICD is based on its...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Condition:   Skin Sensitisation Intervention:   Device: NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Sponsor:   YTY Industry (Manjung) Sdn Bhd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Atopic Dermatitis;   Staphylococcus Aureus;   Bacterial Toxins;   Immune Response;   Cytokines;   T Cells Subsets Intervention:   Other: Skin biopsies and blood samples Sponsor:   Poitiers University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Skin Sensitisation Intervention:   Device: NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Sponsor:   YTY Industry (Manjung) Sdn Bhd Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Atopic Dermatitis;   Staphylococcus Aureus;   Bacterial Toxins;   Immune Response;   Cytokines;   T Cells Subsets Intervention:   Other: Skin biopsies and blood samples Sponsor:   Poitiers University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Due to the high rate of colonization, patients with atopic dermatitis are at risk of S. aureus bloodstream infection, the most severe manifestation of S. aureus infections. Intravascular devices and the skin are the major portals of entry for S. aureus in AD. With prompt and adequate diagnostic and therapeutic management, mortality is lower than in Non-AD patients with SAB and severe sequelae can be averted. Important preventive strategies include AD treatment to reduce S. aureus colonization and meticulous care of intravascular catheters, which should not be placed in/on lesional atopic skin.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research
Condition:   Atopic Dermatitis Intervention:   Drug: Mometasone Furoate Sponsor:   Libbs Farmacêutica LTDA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Atopic Dermatitis Interventions:   Drug: RPT193;   Drug: Placebo Sponsor:   RAPT Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dermatitis | Dermatology | Research